Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $450 price target on Regeneron following his visit to the company’s headquarters this week, saying the management was increasingly more confident about the trajectory of Dupixent. With shares recovering in recent days, the analyst recommends that investors continue to hold the stock, suggesting that concerns over potential competitive threats to Eylea may be overblown in the near term. Raymond also anticipates “significant news flow on the earlier-stage pipeline front in coming quarters” for Regeneron
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.